STOCK TITAN
  1. Home
  2. Sec-filings
  3. BHVN
  4. [8-K] Biohaven Ltd. Reports Material Event

Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Biohaven Ltd. announced several scientific leadership changes. Effective July 13, 2026, Bruce Car, Ph.D., will retire as Chief Scientific Officer and move to a part-time role as Chief Innovation Officer, focusing on scientific initiatives and external collaborations, including multiple assets in the collaboration with Bexorg, Inc. He will continue as an executive officer and his salary will be reduced by fifty percent to reflect his schedule.

At the same time, David Pirman, Ph.D., is promoted to Executive Vice President and Head of Discovery, leading Biohaven’s internal drug-discovery organization and research programs. The company also designated Warren Volles, General Counsel and Chief Legal Officer, as an executive officer, formalizing his role in guiding Biohaven’s legal function.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Effective date of role changes July 13, 2026 Bruce Car retirement as CSO and start as Chief Innovation Officer
Salary reduction for Bruce Car 50% Reflects transition to part-time Chief Innovation Officer role
Collaboration start date June 2025 Start of multi-program research collaboration with Bexorg, Inc.
Chief Innovation Officer financial
"will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer"
executive officer financial
"Dr. Car will continue to serve as an executive officer of the Company"
Head of Discovery financial
"has been promoted to Executive Vice President and Head of Discovery"
multi-program research collaboration financial
"announced a multi-program research collaboration to identify, de-risk, and advance next-generation therapies"
pharmacokinetic and pharmacodynamic technical
"to generate biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What leadership changes did Biohaven (BHVN) announce in this 8-K?
Biohaven announced that Bruce Car, Ph.D., will retire as Chief Scientific Officer and become part-time Chief Innovation Officer, while David Pirman, Ph.D., is promoted to Executive Vice President and Head of Discovery, and Warren Volles is designated an executive officer.

When does Bruce Car’s role change at Biohaven (BHVN) take effect?
Bruce Car’s transition from Chief Scientific Officer to part-time Chief Innovation Officer becomes effective July 13, 2026. He will focus on advancing scientific initiatives and external collaborations, including Biohaven’s multi-program research collaboration with Bexorg, Inc., while remaining an executive officer.

What is the new position of David Pirman at Biohaven (BHVN)?
David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this role, he will lead Biohaven’s internal drug-discovery organization and oversee research programs, supporting the company’s discovery efforts across its pipeline of drug candidates.

How will Bruce Car’s compensation change after his transition at Biohaven?
Following his move to a part-time Chief Innovation Officer role, Bruce Car’s salary will be reduced by fifty percent. This change is described as reflecting his part-time work schedule while he continues to serve as an executive officer and lead external collaborations, including with Bexorg.

What is the Biohaven–Bexorg collaboration mentioned in the filing?
In June 2025, Biohaven and Bexorg, Inc. entered a multi-program research collaboration to identify and advance next-generation therapies for CNS disorders using Bexorg’s whole-brain discovery platform to generate target engagement, biomarker, pharmacokinetic and pharmacodynamic data for Biohaven’s preclinical programs.

Who else was designated an executive officer at Biohaven (BHVN)?
Biohaven designated Warren Volles, its General Counsel and Chief Legal Officer, as an executive officer. He will continue leading the company’s legal function while formally joining the group of executive officers disclosed to investors in this leadership-focused filing and press release.
0001935979false00019359792026-07-092026-07-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 9, 2026
Biohaven Ltd.
(Exact name of registrant as specified in its charter)
British Virgin Islands001-41477Not applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
c/o Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven, Connecticut 06510
(Address of principal executive offices, including zip code)
(203) 404-0410
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of each exchange on which registered
Common Shares, no par valueBHVNNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 9, 2026, Biohaven Ltd. (the “Company”) and Bruce Car, Ph.D., mutually agreed that, effective July 13, 2026, Dr. Car will retire as Chief Scientific Officer of the Company and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer. As Chief Innovation Officer, Dr. Car will focus on advancing Biohaven’s scientific initiatives and external collaborations, including leading multiple assets under the Company’s collaboration with Bexorg, Inc. Dr. Car will continue to serve as an executive officer of the Company. In connection with this transition, David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, effective July 13, 2026. In this role, Dr. Pirman will lead the Company’s internal drug-discovery organization, overseeing research programs.

In connection with his transition to a part-time role, Dr. Car’s salary will be reduced by fifty percent (50%) to reflect his work schedule.

There are no arrangements or understandings between Dr. Car and any other persons pursuant to which he agreed to transition to a part-time role. There are no related party transactions between Dr. Car and the Company that would require disclosure under Item 401(a) of Regulation S-K.

A copy of the press release issued by the Company on July 9, 2026, announcing the transition of Dr. Car is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit NumberExhibit Description
99.1
Press Release, Dated July 9, 2026, “Biohaven Announces Scientific Leadership Transitions”
104The cover page of this Current Report on Form 8-K formatted as Inline XBRL.


2

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 9, 2026
Biohaven Ltd.
By:/s/ Matthew Buten
Matthew Buten
Chief Financial Officer


3
Exhibit 99.1

Biohaven Announces Scientific Leadership Transitions

•David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery
•Bruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external collaborations
•Warren Volles, General Counsel and Chief Legal Officer, also designated an executive officer

NEW HAVEN, Conn., July 9, 2026 — Biohaven Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) today announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery. In this role, Dr. Pirman will lead the Company’s internal drug-discovery organization, overseeing research programs.
Dr. Car is retiring as Chief Scientific Officer and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer, effective July 13, 2026. In this role, Dr. Car will focus on advancing Biohaven’s scientific initiatives and external collaborations including leading multiple assets under the Company’s collaboration with Bexorg, Inc. Dr. Car will continue to serve as an executive officer of the Company.
Warren Volles, General Counsel and Chief Legal Officer, has also been designated an executive officer of Biohaven and will continue to lead the Company's legal function.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, said, “We thank Bruce as he has played a central role in building Biohaven’s scientific foundation and helping translate discovery insights into multiple IND-stage programs across our portfolio. We are pleased that he will continue to bring his expertise to Biohaven in this new part-time role, with a particular focus on our collaboration with Bexorg. David’s promotion reflects his leadership and significant contributions to Biohaven’s discovery efforts, as well as his strong alignment with our continued focus on scientific innovation across our diverse portfolio of drug candidates. Together, these two executive transitions will position us to sustain our discovery momentum and pursue new CNS therapies grounded in human biology and translational innovation.”
Dr. Bruce Car added, "The timing of my retirement and transition reflects my complete confidence in Biohaven’s discovery research platforms and leadership, and genuine excitement for the future of the Biohaven portfolio.”
About the Biohaven–Bexorg Collaboration
In June 2025, Biohaven and Bexorg, Inc., a New Haven-based techbio company, announced a multi-program research collaboration to identify, de-risk, and advance next-generation therapies for CNS disorders. Under the collaboration, Bexorg's whole-brain discovery platform is used to demonstrate target engagement in relevant cell types and tissues and to generate biomarkers,

Exhibit 99.1
pharmacokinetic and pharmacodynamic relationships, and other mechanistic data supporting Biohaven preclinical programs.
About Biohaven
Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies for people with debilitating diseases, with a broad pipeline spanning neuroscience, immunology, and other therapeutic areas. For more information, visit biohaven.com.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "potentially", "potentially groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations, Biohaven
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741

Media Contact:
Mike Beyer
Sam Brown Healthcare Communications
mikebeyer@sambrown.com
+1 (312) 961-2502


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents